Cabozantinib inhibits tumor growth and metastasis of a patient-derived xenograft model of papillary renal cell carcinoma with MET mutation

References

• Twardowski PW, Mack PC, Lara PN, Jr. Papillary renal cell carcinoma: current progress and future directions. Clin Genitourin Cancer 2014; 12:74-9; PMID:24629521; https://doi.org/10.1016/j.clgc.2013.11.013
   PubMed Web of Science ®Google Scholar
• Courthod G, Tucci M, Di Maio M, Scagliotti GV. Papillary renal cell carcinoma: A review of the current therapeutic landscape. Crit Rev Oncol Hematol 2015; 96:100-12; PMID:26052049; https://doi.org/10.1016/j.critrevonc.2015.05.008
   PubMed Web of Science ®Google Scholar
• Algaba F, Akaza H, Lopez-Beltran A, Martignoni G, Moch H, Montironi R, Reuter V. Current pathology keys of renal cell carcinoma. Eur Urol 2011; 60:634-43; PMID:21741159; https://doi.org/10.1016/j.eururo.2011.06.047
   PubMed Web of Science ®Google Scholar
• Bentz M, Bergerheim US, Li C, Joos S, Werner CA, Baudis M, Gnarra J, Merino MJ, Zbar B, Linehan WM, et al. Chromosome imbalances in papillary renal cell carcinoma and first cytogenetic data of familial cases analyzed by comparative genomic hybridization. Cytogenet Cell Genet 1996; 75:17-21; PMID:8995481; https://doi.org/10.1159/000134448
   PubMedGoogle Scholar
• Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997; 16:68-73; PMID:9140397; https://doi.org/10.1038/ng0597-68
   PubMed Web of Science ®Google Scholar
• Salvi A, Marchina E, Benetti A, Grigolato P, De Petro G, Barlati S. Germline and somatic c-met mutations in multifocal/bilateral and sporadic papillary renal carcinomas of selected patients. Int J Oncol 2008; 33:271-6; PMID:18636147; https://doi.org/10.3892/ijo_00000006
   PubMed Web of Science ®Google Scholar
• Sweeney P, El-Naggar AK, Lin SH, Pisters LL. Biological significance of c-met over expression in papillary renal cell carcinoma. J Urol 2002; 168:51-5; PMID:12050491; https://doi.org/10.1016/S0022-5347(05)64830-6
   PubMed Web of Science ®Google Scholar
• Albiges L, Guegan J, Le Formal A, Verkarre V, Rioux-Leclercq N, Sibony M, Bernhard JC, Camparo P, Merabet Z, Molinie V, et al. MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array. Clin Cancer Res 2014; 20:3411-21; PMID:24658158; https://doi.org/10.1158/1078-0432.CCR-13-2173
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network, Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, Wheeler DA, Murray BA, Schmidt L, et al. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Eng J Med 2016; 374:135-45; PMID:26536169; https://doi.org/10.1056/NEJMoa1505917
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Dutcher J. Targeted therapies and the treatment of non-clear cell renal cell carcinoma. Ann Oncol 2013; 24:1730-40; PMID:23625974; https://doi.org/10.1093/annonc/mdt152
   PubMed Web of Science ®Google Scholar
• Schmidinger M. Improving outcomes in metastatic clear cell renal cell carcinoma by sequencing therapy. Am Soc Clin Oncol Educ Book 2014:e228-38; PMID:24857107; https://doi.org/10.14694/EdBook_AM.2014.34.e228
   PubMedGoogle Scholar
• Shoji S, Nakano M, Sato H, Tang XY, Osamura YR, Terachi T, Uchida T, Takeya K. The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma. Clin Exp Metastasis 2014; 31:111-34; PMID:23959576; https://doi.org/10.1007/s10585-013-9612-7
   PubMed Web of Science ®Google Scholar
• Thomas JS, Kabbinavar F. Metastatic clear cell renal cell carcinoma: A review of current therapies and novel immunotherapies. Crit Rev Oncol Hematol 2015; 96:527-33; PMID:26299335; https://doi.org/10.1016/j.critrevonc.2015.07.009
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska e, Sosman J, McDermott D, Bodrogi I, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Eng J Med 2007; 356:2271-81; PMID:17538086; https://doi.org/10.1056/NEJMoa066838
   PubMed Web of Science ®Google Scholar
• Stadler WM, Figlin RA, McDermott DF, Dutcher JP, Knox JJ, Miller WH, Jr., Hainsworth JD, Henderson CA, George JR, Hajdenberg J, et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 2010; 116:1272-80; PMID:20082451; https://doi.org/10.1002/cncr.24864
   PubMed Web of Science ®Google Scholar
• Escudier BJ, Ravaud A, Négrier S, Szczylik C, Bellmunt Molins J, Bracarda, P. Pisa S, Gaudreault J and Bajetta E. Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): Efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis. J Clin Oncol 2008; 26(suppl 155): abstract 5025.
   Google Scholar
• Ingels A, Zhao H, Thong AE, Saar M, Valta MP, Nolley R, Santos J, Peehl DM. Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts. Int J Cancer 2014; 134:2322-9; PMID:24243565; https://doi.org/10.1002/ijc.28579
   PubMed Web of Science ®Google Scholar
• Thong AE, Zhao H, Ingels A, Valta MP, Nolley R, Santos J, Young SR, Peehl DM. Tissue slice grafts of human renal cell carcinoma: an authentic preclinical model with high engraftment rate and metastatic potential. Urol Oncol 2014; 32:43 e23-30; PMID:23911681; https://doi.org/10.1016/j.urolonc.2013.05.008
   PubMed Web of Science ®Google Scholar
• Truong LD, Shen SS. Immunohistochemical diagnosis of renal neoplasms. Arch Pathol Lab Med 2011; 135:92-109; PMID:21204715; https://doi.org/10.1043/2010-0478-RAR.1
   PubMed Web of Science ®Google Scholar
• Jeffers M, Schmidt L, Nakaigawa N, Webb CP, Weirich G, Kishida T, Zbar B, Vande Woude GF. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci U S A 1997; 94:11445-50; PMID:9326629; https://doi.org/10.1073/pnas.94.21.11445
   PubMed Web of Science ®Google Scholar
• Nakaigawa N, Weirich G, Schmidt L, Zbar B. Tumorigenesis mediated by MET mutant M1268T is inhibited by dominant-negative Src. Oncogene 2000; 19:2996-3002; PMID:10871851; https://doi.org/10.1038/sj.onc.1203628
   PubMed Web of Science ®Google Scholar
• Fallahi P, Ferrari SM, Di Bari F, Materazzi G, Benvenga S, Miccoli P, Antonelli A. Cabozantinib in Thyroid Cancer. Recent Pat Anti-cancer Drug Discov 2015; 10:259-69; PMID:26152149; https://doi.org/10.2174/1574892810666150708110816
   PubMed Web of Science ®Google Scholar
• Goetsch L, Caussanel V, Corvaia N. Biological significance and targeting of c-Met tyrosine kinase receptor in cancer. Front Biosci 2013; 18:454-73; PMID:23276936; https://doi.org/10.2741/4114
   PubMed Web of Science ®Google Scholar
• Bentzien F, Zuzow M, Heald N, Gibson A, Shi Y, Goon L, Yu P, Engst S, Zhang W, Huang D, et al. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer. Thyroid 2013; 23:1569-77; PMID:23705946; https://doi.org/10.1089/thy.2013.0137
   PubMed Web of Science ®Google Scholar
• Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Bentzien F, Cancilla B, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011; 10:2298-308; PMID:21926191; https://doi.org/10.1158/1535-7163.MCT-11-0264
   PubMed Web of Science ®Google Scholar
• Ma M, Zhu H, Zhang C, Sun X, Gao X, Chen G. “Liquid biopsy”-ctDNA detection with great potential and challenges. Ann Transl Med 2015; 3:235; PMID:26539452; https://doi.org/10.3978/j.issn.2305-5839.2015.09.29
   PubMed Web of Science ®Google Scholar
• Gingras I, Salgado R, Ignatiadis M. Liquid biopsy: will it be the ‘magic tool’ for monitoring response of solid tumors to anticancer therapies? Curr Opin Oncol 2015; 27:560-7; PMID:26335664; https://doi.org/10.1097/CCO.0000000000000223
   PubMed Web of Science ®Google Scholar
• Schuller AG, Barry ER, Jones RD, Henry RE, Frigault MM, Beran G, Linsenmayer D, Hattersley M, Smith A, Wilson J, et al. The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models. Clin Cancer Res 2015; 21:2811-9; PMID:25779944; https://doi.org/10.1158/1078-0432.CCR-14-2685
   PubMed Web of Science ®Google Scholar
• Bianchi M, Sun M, Jeldres C, Shariat SF, Trinh QD, Briganti A, Tian Z, Schmitges J, Graefen M, Perrotte P, et al. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol 2012; 23:973-80; PMID:21890909; https://doi.org/10.1093/annonc/mdr362
   PubMed Web of Science ®Google Scholar
• Valta MP, Zhao H, Ingels A, Thong AE, Nolley R, Saar M, Peehl DM. Development of a realistic in vivo bone metastasis model of human renal cell carcinoma. Clin Exp Metastasis 2014; 31:573-84; PMID:24715498; https://doi.org/10.1007/s10585-014-9651-8
   PubMed Web of Science ®Google Scholar
• Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 2008; 34:193-205; PMID:18313224; https://doi.org/10.1016/j.ctrv.2007.12.001
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Pal SK, McDermott DF, Morrissey S, Ferguson KC, Holland J, Kaelin WG, Dutcher JP. A phase I study of cabozantinib (XL184) in patients with renal cell cancer. Ann Oncol 2014; 25:1603-8; PMID:24827131; https://doi.org/10.1093/annonc/mdu184
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, et al. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Eng J Med 2015; 373:1814-23; PMID:26406150; https://doi.org/10.1056/NEJMoa1510016
   PubMed Web of Science ®Google Scholar
• Rankin EB, Fuh KC, Castellini L, Viswanathan K, Finger EC, Diep AN, LaGory EL, Kariolis MS, Chan A, Lindgren D, et al. Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET. Proc Natl Acad Sci U S A 2014; 111:13373-8; PMID:25187556; https://doi.org/10.1073/pnas.1404848111
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol 2013; 31:181-6; PMID:23213094; https://doi.org/10.1200/JCO.2012.43.3383
   PubMed Web of Science ®Google Scholar
• Katayama R, Aoyama A, Yamori T, Qi J, Oh-hara T, Song Y, Engelman JA, Fujita N. Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. Cancer Res 2013; 73:3087-96; PMID:23598276; https://doi.org/10.1158/0008-5472.CAN-12-3256
   PubMed Web of Science ®Google Scholar
• Diamond JR, Salgia R, Varella-Garcia M, Kanteti R, LoRusso PM, Clark JW, Xu LG, Wilner K, Eckhardt SG, Ching KA, et al. Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma. J Clin Oncol 2013; 31:e254-8; PMID:23610116; https://doi.org/10.1200/JCO.2012.46.4289
   PubMed Web of Science ®Google Scholar
• Thierry AR, Mouliere F, Gongora C, Ollier J, Robert B, Ychou M, Del Rio M, Molina F. Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. Nucleic Acids Res 2010; 38:6159-75; PMID:20494973; https://doi.org/10.1093/nar/gkq421
   PubMed Web of Science ®Google Scholar
• Gorges TM, Schiller J, Schmitz A, Schuetzmann D, Schatz C, Zollner TM, Krahn T, von Ahsen O. Cancer therapy monitoring in xenografts by quantitative analysis of circulating tumor DNA. Biomarkers 2012; 17:498-506; PMID:22616911; https://doi.org/10.3109/1354750X.2012.689133
   PubMed Web of Science ®Google Scholar
• Tsao SC, Weiss J, Hudson C, Christophi C, Cebon J, Behren A, Dobrovic A. Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations. Sci Rep 2015; 5:11198; PMID:26095797; https://doi.org/10.1038/srep11198
   PubMed Web of Science ®Google Scholar
• Zhao H, Nolley R, Chen Z, Peehl DM. Tissue slice grafts: an in vivo model of human prostate androgen signaling. Am J Pathol 2010; 177:229-39; PMID:20472887; https://doi.org/10.2353/ajpath.2010.090821
   PubMed Web of Science ®Google Scholar
• Graham TJ, Box G, Tunariu N, Crespo M, Spinks TJ, Miranda S, Attard G, de Bono J, Eccles SA, Davies FE, et al. Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib. J Natl Cancer Inst 2014; 106:dju033; PMID:24634505; https://doi.org/10.1093/jnci/dju033
   PubMedGoogle Scholar
• Holdenrieder S, Mueller S, Stieber P. Stability of nucleosomal DNA fragments in serum. Clin Chem 2005; 51:1026-9; PMID:15914786; https://doi.org/10.1373/clinchem.2005.048454
   PubMed Web of Science ®Google Scholar